EP1994017A2 - Nouveaux inhibiteurs hétérocycliques de nf/kb - Google Patents

Nouveaux inhibiteurs hétérocycliques de nf/kb

Info

Publication number
EP1994017A2
EP1994017A2 EP07711946A EP07711946A EP1994017A2 EP 1994017 A2 EP1994017 A2 EP 1994017A2 EP 07711946 A EP07711946 A EP 07711946A EP 07711946 A EP07711946 A EP 07711946A EP 1994017 A2 EP1994017 A2 EP 1994017A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
aryl
haloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07711946A
Other languages
German (de)
English (en)
Inventor
Johann Leban
Harald Schmitt
Kristina Wolf
Stefano Pegoraro
Andreas Wuzik
Rolf Krauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4SC AG
Original Assignee
4SC AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/375,259 external-priority patent/US7601745B2/en
Priority claimed from PCT/EP2006/002396 external-priority patent/WO2007016979A2/fr
Application filed by 4SC AG filed Critical 4SC AG
Priority to EP07711946A priority Critical patent/EP1994017A2/fr
Publication of EP1994017A2 publication Critical patent/EP1994017A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds of the general formula (Ia), (Ib), (Ic), (Di), (II), or (III) or a stereoisomer thereof or possible pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs of these compounds.
  • the compounds of the invention can be used as a medicament and are exceptionally useful for the treatment of diseases associated with abnormal and hyperproliferation of cells in mammals, especially in humans, hi particular, they are useful for the treatment of diseases characterized by a hyperproliferation of T-cells.
  • the present invention relates to compounds which are suitable for the therapy of diseases that can be treated by modulating cellular pathways in eukaryotes, e.g. cancer, immunological or inflammatory disorders, and viral infections, to processes for the preparation of these compounds, and to their use.
  • T-cell homeostasis is critical for the maintenance of immune tolerance. Defects in T-cell homeostasis can lead to autoimmune pathology. Autoimmune diseases include a large spectrum of clinically distinct entities that share a common aetiology, a misguided, self- directed immune response. This immune response can also be the consequence of an organ transplant. Evidence suggests a prime role of T-cell reactivity in autoimmune diseases. Measuring proliferative responses in T-lymphocytes is a widely used assay to measure immune competence (Killestein, J. et al. J. Neuroimmunol. 133,217-24, 2002).
  • PBMCs Peripheral blood mononuclear cells
  • the major neutral proteolytic activity in the cytosol and nucleus is the proteasome, a 2OS (700 kDa) particle with multiple peptidase activities.
  • the continual turnover of cellular proteins by the ubiquitin-proteasome pathway is used by the immune system to screen for the presence of abnormal intracellular proteins (Dantuma, N.P. et al. Nat. Biotechnol. 2000, 18(5), 538-43; Goldberg, AL. et al. Nature 357, 375, 1993).
  • the ubiquitin- proteasome pathway plays an essential role in the regulation of NF- ⁇ B activity, being responsible for the degradation of the inhibitor I ⁇ B- ⁇ .
  • I ⁇ B- ⁇ In order to be targeted for degradation by the proteasome, I ⁇ B- ⁇ must first undergo selective phosphorylation at serine residues 32 and 36, followed by ubiquitinylation (Chen, ZJ. et al. Cell 84, 853-862, 1996; Brown, K. et al. Science 267, 1485, 1995).
  • NF- ⁇ B a transcription factor, regulates the transcription of an important set of genes, involved in inflammatory responses (Baeuerle, PA. et al. Cell 87, 1, 13-20, 1996).
  • Proteasome inhibitors block I ⁇ B- ⁇ degradation and NF- ⁇ B activation (Traeckner et al. EMBOJ. 13, 5433, 1994).
  • NF- ⁇ B Nuclear Factor- KB
  • NF- ⁇ B is a eukaryotic transcription factor of the rel family, which is located in the cytoplasm in an inactive complex, as a homo- or heterodimer. Predominantly it exists as a heterodimer composed of p50 and p65 subunits, bound to inhibitory proteins of the IKB family, usually I ⁇ B- ⁇ (D. Thanos et al, Cell 80, 529, 1995).
  • NF-KB is activated in response to different stimuli, among which inflammatory cytokines, UV radiation, phorbol esters, bacterial and viral infections.
  • NF- ⁇ B Stimulation triggers the release of NF- ⁇ B from IKB in consequence of the phosphorylation and the following degradation of the IKB- ⁇ protein (P. A. Baeuerle et al, Annu. Rev. Immunol. 12, 141, 1995) by the proteasome.
  • NF- ⁇ B translocates in the nucleus where it binds to the DNA at specific ⁇ B-sites and induces the transcription of a variety of genes encoding proteins involved in controlling the immune and inflammatory responses, amongst others interleukins, TNF- ⁇ , the NO-synthase and the cyclooxygenase 2 (S. Grimm et al, J. Biochem. 290, 297, 1993).
  • NF- ⁇ B is considered an early mediator of the immune and inflammatory responses and it is involved in the control of cell proliferation and in the pathogenesis of various human diseases, such as rheumatoid arthritis (H. Beker et al, Clin. Exp. Immunol. 99, 325, 1995), ischemia (A. Salminen et al, Biochem. Biophys. Res. Comm. 212, 939, 1995), arteriosclerosis (A.S. Baldwin, Annals Rev. Immunol. 212, 649, 1996), as well as in the pathogenesis of AIDS.
  • rheumatoid arthritis H. Beker et al, Clin. Exp. Immunol. 99, 325, 1995
  • ischemia A. Salminen et al, Biochem. Biophys. Res. Comm. 212, 939, 1995
  • arteriosclerosis A.S. Baldwin, Annals Rev. Immunol. 212, 649, 1996), as well as in the
  • Inhibition of NF- ⁇ B mediated gene transcription can be accomplished through inhibition of phosphorylation of the inhibitory protein IKB, inhibition of IKB degradation, inhibition of NF- ⁇ B (p50/p65) nuclear translocation, the inhibition of NF-KB-DNA binding or NF- ⁇ B-mediated DNA transcription (J.C. Epinat et al, Oncogene 18, 6896, 1999).
  • the present invention relates to compounds of the general formula (Ia) or a pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof,
  • R is independently hydrogen, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R 1 is independently alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • X is CO, CS or SO 2 ;
  • Y is CO, CS or SO 2 ;
  • Z is NR 2' , S, or O;
  • R 2' is H, alkyl, -C(O)NR 7 , -C(O)R 6 , cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl;
  • R c is independently H, OH, SH, NROR 1 , NH 2 , alkylamino, hydroxyalkylamino, halogen, C0NR d R e , alkoxy, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R 7 , R 7 independently represent H, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl;
  • R is H, NH 2 , alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl;
  • R 2 is independently
  • R 5 is independently H, COR 6 , CO 2 R 6 , SOR 6 , SO 2 R 6 , SO 3 R 6 , alkyl, cycloalkyl, alkoxy, -NH 2 , alkylamine, -NR 7 COR 6 , halogen, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
  • R 6 is independently H, alkyl, cycloalkyl, amino, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, aryl or heteroaryl;
  • an alkyl group denotes a linear or branched CrC ⁇ -alkyl, preferably a linear or branched chain of one to five carbon atoms, a linear or branched Cr-C 6 -alkenyl or a linear or branched C 2 -C 6 -alkinyl group, which can optionally be substituted by one or more substituents R';
  • R- is independently H, -CO 2 R' ', -C0NHR ⁇ ⁇ -CR" O, -SO 2 NR " , -NR"-CO-haloalkyl, -NO 2 , -NR"-SO 2 -haloalkyl, -NR"-SO 2 -alkyl, -SO 2 -alkyl, -NR " -CO-alkyl, -CN, alkyl, cycloalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy. aryl, or heteroaryl;
  • R" is independently H, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, or heteroaryl; a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group E, E being O, S, SO, SO 2 , N, or NR", R" being as defined above; the C 3 -C 8 -CyClOaIlCyI residue may be selected from the group comprising
  • an alkoxy group denotes an O-alkyl group, the alkyl group being as defined above; the alkoxy group is preferably a methoxy, ethoxy, isopropoxy, t-butoxy or pentoxy group; an alkylthio group denotes an S-alkyl group, the alkyl group being as defined above; a haloalkyl group denotes an alkyl group which is substituted by one to five halogen atoms, the alkyl group being as defined above; the haloalkyl group is preferably a -C(R 10 ) 3
  • a hydroxyalkyl group denotes an HO-alkyl group, the alkyl group being as defined above;
  • a haloalkyloxy group denotes an alkoxy group which is substituted by one to five halogen atoms, the alkyl group being as defined above; the haloalkyloxy group is preferably a
  • R 10 represent F, Cl, Br or I, preferably F; a hydroxyalkylamino group denotes an (HO-alkyl) 2 -N- group or HO-alkyl-NH- group, the alkyl group being as defined above; an alkylamino group denotes an HN-alkyl or N-dialkyl group, the alkyl group being as defined above; a halogen group is chlorine, bromine, fluorine or iodine; an aryl group denotes an aromatic group having five to fifteen carbon atoms, which can optionally be substituted by one or more substituents R ⁇ where R' is as defined above; the aryl group is preferably a benzyl group, a phenyl group, -0-C 6 H 4 - R ⁇ -In-C 6 H 4 - R ⁇ — p—
  • heteroaryl group denotes a 5- or 6-membered heterocyclic group which contains at least one heteroatom selected from O, N, and S. This heterocyclic group can be fused to another aromatic ring.
  • this group can be selected from a thiadiazole, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, benzooxazol-2-yl, benzooxazol-4-yl, benzooxazol-5-yl, benzoisooxazol-3-yl, benzoisooxazol-4-yl, benzoisooxazol-5-yl, l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, l,2,5-oxadiazol-3-yl,
  • the present invention relates to compounds of the general formula (Ib) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof,
  • R 1 is -C(O)R 7 , -C(O)CHR 7 R 8 , -C(O)NR 7 R 8 , -C(O)OR 7 , -R 7 C(O)R 8 , or -C(S)R 7 ;
  • R* independently represents H, -CN, -OH, -SH, -CO 2 R 4' , -C(O)R 4' , -SO 2 NR 4' ,
  • R 4 is H, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl; or R 1 and R 4 together with the X to which they are attached form a 3 to 8 membered saturated or at least partially unsaturated monocyclic or polycyclic ring system, wherein at least one ring atom is a heteroatom selected from O, N, and S, and the ring optionally has one or more substituents R ;
  • X is N, or CR 2' ;
  • Y is CO, CS or SO 2 ;
  • Z is NR 2" , S, or O;
  • R 2" is H, alkyl, -C(O)NR 7 , -C(O)R e , cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl;
  • R 2' is H, alkyl, -C(O)N R 4' , -C(O) R 4' , cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl;
  • p is 1 to 6;
  • q is 1 to 6;
  • R a is independently H, OH, SH, NH
  • R b is independently H, OH, SH, NH 2 , alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, alkoxy, alkylamino, hydroxyalkylamino, halogen, aryl, or heteroaryl;
  • R c is independently H, OH, SH, NR 4 OR 5' , NH 2 , alkylamino, hydroxyalkylamino, halogen, CONR d R e , alkoxy, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R 8 is H, NH 2 , alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl;
  • -NR 4' -CO-haloalkyl -NO 2 , -NR 4' -SO 2 -haloalkyl, -NR 4' -SO 2 -alkyl, -NR 4' -CO-alkyl, -NR 4 (CH 2 ) p heteroaryl, alkyl, hydroxyalkyl, cycloalkyl, alkylamino, hydroxyalkylamino, alkoxy, alkylthio, -O(CH 2 ) p [O(CH 2 ) p ] q OCH 3 , -C(NR 4" )NR 4' benz- imidazolyl, -C(NR 4" )NR 4' benzthiazolyl, -C(NR 4" )NR 4' benzoxazolyl, aryl or heteroaryl;
  • R 2 is independently
  • A is N, O, or CR 2' ;
  • R 5 is independently H, SOR 7 , SO 2 R 7 , SO 3 R 7 , -C(O)R 7 , -C(O)CHR 7 R 8 , -C(O)NR 7 R 8 , -
  • an alkyl group if not stated otherwise, denotes a linear or branched CrC ⁇ -alkyl, preferably a linear or branched chain of one to five carbon atoms, a linear or branched C 2 -C 6 -alkenyl or a linear or branched C 2 -C 6 -alkinyl group, which can optionally be substituted by one or more substituents R ⁇ ;
  • R ⁇ is independently H, -CO 2 R", -CONHR", -CR"O, -SO 2 NR", -NR"-CO-haloalkyl,
  • -NO 2 -NR"-SO 2 -haloalkyl, -NR"-SO 2 -alkyl, -SO 2 -alkyl, -NR"-CO-alkyl, -CN, alkyl, cycloalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R" is independently H, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, or heteroaryl;
  • a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group E, E being O, S, SO, SO 2
  • This heterocyclic group can be fused to another aromatic ring.
  • this group can be selected from a thiadiazole, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, benzooxazol-2-yl, benzooxazol-4-yl, benzooxazol-5-yl, benzoisooxazol-3-yl, benzoisooxazol-4-yl, benzoisooxazol-5-yl, l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl,
  • the present invention relates to compounds of the general formula (Ic) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof,
  • R 1 independently represents H, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • X is CO, CS or SO 2 ;
  • Y is CO, CS or SO 2 ;
  • Z is NR 2" , S, or O;
  • R 2" is H, alkyl, -C(O)NR 7 , -C(O)R 6 , cycloalkyl, haloalkyl, hydroxyalkyl, hydroxy- alkylamino, alkylamino, heteroaryl, or aryl;
  • S is 0, or 1
  • R b is independently H, OH, SH, NR 4' ⁇ R 5' , NH 2 , alkylamino, hydroxyalkylamino, halogen, CONR d R e , alkoxy, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R c is independently H, OH 5 SH, NR 4' ⁇ R 5' , NH 2 , alkylamino, hydroxyalkylamino, halogen, CONR d R e , alkoxy, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R 3 is independently H, OH, SH, NR 4 OR 5 , NH 2 , hydroxyalkylamino, alkylamino, halogen, CONR R e , alkoxy, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • an alkyl group denotes a linear or branched C]-C 6 -alkyl, preferably a linear or branched chain of one to five carbon atoms, a linear or branched C 2 -C 6 -alkenyl or a linear or branched C 2 - C 6 -alkinyl group, which can optionally be substituted by one or more substituents R';
  • R ⁇ is independently H, -CO 2 R", -CONHR", -CR"O, -SO 2 NR", -NR"-CO-haloalkyl,
  • R ⁇ ' is independently H, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, or heteroaryl;
  • a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group E, E being O, S, SO, SO 2
  • R 10 , R 10' , R 10" represent F, Cl, Br or I, preferably F;
  • a hydroxyalkyl group denotes an HO-alkyl group, the alkyl group being as defined above;
  • a haloalkyloxy group denotes an alkoxy group which is substituted by one to five halogen atoms, the alkyl group being as defined above;
  • the haloalkyloxy group is preferably a -OC(R 10 ) 3 , -OCR 10 (R 10' ) 2 , -OCR 10 (R 10' )R 10" , -OC 2 (R I0 ) 5 , -OCH 2 -C(R 10 ) 3 , -OCH 2 -CR 10 (R 10' ) 2 , -OCH 2 -CR 10 (R 10' )R 10" , -OC 3 (R 10 ) 7 or -
  • This heterocyclic group can be fused to another aromatic ring.
  • this group can be selected from a thiadiazole, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, benzooxazol-2-yl, benzooxazol-4-yl, benzooxazol-5-yl, benzoisooxazol-3-yl, benzoisooxazol-4-yl, benzoisooxazol-5-yl, l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl,
  • the present invention also relates to compounds of the general formula (III) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof,
  • R 1 is -C(O)R 7a , -C(O)CHR 7 R 8 , -C(O)NR 7 R 8 , -C(O)OR 7 , -R 7 C(O)R 8 , or -C(S)R 76 :
  • R 2 is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or R 1 and R 2 together with the N-atom or the C-atom to which they are attached form a 3 to 8 membered saturated or at least partially unsaturated monocyclic or polycylic ring system, wherein at least one or more of the carbon atoms in the ring is a heteroatom selected from O, N, and S, and the ring can be substituted by one or more R 9 ;
  • R 4a is H, Ci-C ⁇ -alkyl, Cr-C 6 -alkenyl, cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, -C(NR 7 )NR 7> R 8 , -(CH 2 ) p aryl, -(CH 2 ) P NR 7 R
  • R 3 is H, -C(0)NR a R b , halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR 4 OR 5' , NH 2 , hydroxyalkylamino, alkylamino, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl, or haloalkyloxy;
  • R 71 " is H, halogen, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, heteroaryl, or aryl;
  • A is CO or SO 2 ;
  • X is NR 2' , O, or S;
  • Z is N or CR 2' ;
  • R 2' is H, alkyl, -C(O)NR 7 , -C(O)R b , cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl; p is 1 to 6; q is 1 to 6; R 9 independently represents H, -CN, -OH, -SH, alkoxy, alkylthio, -CO 2 R 4' , -C(0)R 4a ,
  • -NR 4' -CO-alkyl -NR 4' (CH 2 ) p heteroaryl, alkyl, hydroxyalkyl, cycloalkyl, halogen, haloalkyl, alkylamino, -O(CH 2 ) p [O(CH 2 ) p ] q OCH 3 , -C(NR 4" )NR 4' benzimidazolyl, -C(NR 4" )NR 4' benzthiazolyl, -C(NR 4" )NR 4' benzoxazolyl, hydroxycycloalkyl, hydroxyalkylamino, haloalkyloxy, heterocycloalkyl, -(CH 2 ) P NR COR , aryl, or heteroaryl;
  • Ci-C 6 -alkyl group if not stated otherwise, denotes a linear or branched Q-Q-alkyl, preferably a linear or branched chain of one to five carbon atoms, which can optionally be substituted by one or more substituents R";
  • a C 2 -C 6 -alkenyl group if not stated otherwise, denotes a linear or branched Cr-Q-alkenyl, preferably a linear or branched chain of two to six carbon atoms, which can optionally be substituted by one or more substituents R' ;
  • an alkyl group if not stated otherwise, denotes a linear or branched CrQ-alkyl, preferably a linear or branched chain of one to six carbon atoms, a linear or branched C 2 -C 6 -alkenyl or a linear or branched C 2 -C 6 -alkynyl group, which can be substituted by one or more substituents
  • R ⁇ is independently H, -CO 2 R", -CONHR", -CR"O, -SO 2 NR", -NR"-CO-haloalkyl, -NO 2 , -NR"-SO 2 -haloalkyl, -NR"-SO 2 -alkyl, -SO 2 -alkyl, -NR"-CO-alkyl, -CN, alkyl, cycloalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy, aryl, or heteroaryl;
  • R" is independently H, haloalkyl, hydroxyalkyl, ahcyl, cycloalkyl, aryl, or heteroaryl;
  • a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group R ⁇ being as defined above;
  • the C 3 -C 8 -cycloalkyl residue may be selected from the group comprising -cyclo-C 3 Hs, -cyclo-C 4 H 7 , -cyclo-CsHg, -CyCIo-C 6 H 11 , -cyclo-C 7 H 13 , -CyCIo-C 8 Hi 5
  • a heterocycloalkyl group denotes a non-aromatic ring system containing two to ten carbon atoms and at least one heteroatom selected from O, N,
  • This heterocyclic group can be fused to another aromatic ring.
  • this group can be selected from a thiadiazole, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, benzooxazol-2-yl, benzooxazol-4-yl, benzooxazol-5-yl, benzoisooxazol-3-yl, benzoisooxazol-4-yl, benzoisooxazol-5-yl, l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl,
  • R 1 independently represents hydrogen, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl;
  • R 2 independently represents -NR 3 R 4
  • R 3 independently represents alkyl, cycloalkyl, alkoxy, alkylamine, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl,
  • R 4 independently represents alkyl, cycloalkyl, alkoxy, alkylamine, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
  • R 5 independently represents H, COR 6 , CO 2 R 6 , SOR 6 , SO 2 R 6 , SO 3 R 6 , alkyl, cycloalkyl, alkoxy, -NH 2 , alkylamine, -NR 7 COR 6 , halogen, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
  • R 6 independently represents H, alkyl, cycloalkyl, -NH 2 , alkylamine, aryl or heteroaryl;
  • R 7 independently represents H, alkyl, cycloalkyl, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, aryl, or heteroaryl; p is 0, or 1 ; q is 0, or 1 ; X is CO or SO 2 .
  • the present invention relates also to compounds of the general formula (Ih) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof,
  • A is NR 2' , S or O; t is 0 to 4; r is 0, or 1 ;
  • R 2a is independently H, OH, SH, NH 2 , alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, alkoxy, alkylamino, hydroxyalkylamino, halogen, aryl, or heteroaryl;
  • R 3a is H, OH, SH, NH 2 , -C(NR 7 )NR r R 8 , -(CH 2 ) p aryl, -(CH 2 ) P NR 7 R 8 , -C(O)NR 7 R 8 ,
  • -N CR 7 R 8 , -NR 7 C(O)R 8 , alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, alkoxy, alkylamino, hydroxyalkylamino, halogen, aryl, or heteroaryl;
  • R ⁇ is H, halogen, alkyl, -C(NR 7 )NR 7 R 8 , -(CH 2 ) p aryl, -(CH 2 ) P NR 7 R 8 , -C(O)NR 7 R 8 ,
  • -N CR 7 R 8 , -NR 7 C(O)R 8 , cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl;
  • R 1 is -C(O)R 7a , -C(O)CHR 7 R 8 , -C(O)NR 7 R 8 , -C(O)OR 7 , -R 7 C(O)R 8 , or -C(S)R 7 *;
  • R 2 is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, or heteroaryl; or R 1 and R 2 together with the N-atom or the C-atom to which they are attached form a 3 to 8 membered saturated or at least partially unsaturated monocyclic or polycylic ring system, wherein at least one or more of the carbon atoms in the ring is a heteroatom selected from O, N, and S, and the ring can be substituted by one or more R ;
  • R 4a is H, d-C 6 -alkyl, Cr-Q-alkenyl,
  • R 3 is H, -C(O)NR a R b , halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR 4 OR 5' , NH 2 , hydroxyalkylamino, alkylamino, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl, or haloalkyl oxy;
  • R 7 "7' ⁇ R , R , R independently are H, halogen, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, arylamino heteroaryl, or aryl;
  • R 7a is cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, heteroaryl, or aryl;
  • R n is H, halogen, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, heteroaryl, or aryl;
  • X is NR 2' , O, or S;
  • Z is N or CR 2' ;
  • R 2' is H, alkyl, -C(O)NR 7 , -C(0)R b , cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl; p is 1 to 6; q is 1 to 6;
  • R 9 independently represents H, -CN, -OH, -SH, alkoxy, alkylthio, -CO 2 R 4' , -C(0)R 4a ,
  • -NR 4' -C0-alkyl -NR 4' (CH 2 ) p heteroaryl, alkyl, hydroxyalkyl, cycloalkyl, halogen, haloalkyl, alkylamino, -O(CH 2 ) p [O(CH 2 ) p ] q OCH 3 , -C(NR 4" )NR 4' benzimidazolyl,
  • a C]-C 6 -alkyl group if not stated otherwise, denotes a linear or branched Ci-C 6 -alkyl, preferably a linear or branched chain of one to five carbon atoms, which can optionally be substituted by one or more substituents R % ;
  • a C 2 -C 6 -alkenyl group if not stated otherwise, denotes a linear or branched preferably a linear or branched chain of two to six carbon atoms, which can optionally be substituted by one or more substituents R ⁇ ;
  • an alkyl group if not stated otherwise, denotes a linear or branched CrQ-alkyl, preferably a linear or branched chain of one to six carbon atoms, a linear or branched C 2 -C 6 -alkenyl or a linear or branched C 2 -C 6 -alkynyl group, which can be substituted by one or more substituents R ⁇
  • R ⁇ is independently H, -CO 2 R", -CONHR", -CR"O, -SO 2 NR", -NR"-CO-haloalkyl,
  • R" is independently H, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, or heteroaryl; a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group R ⁇ being as defined above; the C 3 -C 8 -cycloalkyl residue may be selected from the group comprising -cyclo-C 3 H 5 , -cyclo-C 4 H 7 , -CyCIo-C 5 Hg,
  • a heterocycloalkyl group denotes a non-aromatic ring system containing two to ten carbon atoms and at least one heteroatom selected from O, N, and S, wherein one or more of the carbon atoms in the ring can be substituted by R ⁇ being as defined above; preferred heterocycloalkyl groups are morpholine-4-yl, piperazinyl, l-alkylpiperazine-4-yl, piperidinyl, pyrrolidinyl, azepane-1-yl; an alkoxy group denotes an O-alkyl group, the alkyl group being as defined above; the alkoxy group is preferably a methoxy, ethoxy, isopropoxy, /-butoxy or pentoxy group; an alkylthio group denotes an S-alkyl group, the al
  • R 10 , R 10' , R 10" represent F, Cl, Br or I, preferably F;
  • a hydroxyalkylamino group denotes an (HO-alkyl) 2 -N- group or HO-alkyl-NH- group, the alkyl group being as defined above;
  • an alkylamino group denotes an HN-alkyl or N-dialkyl group, the alkyl group being as defined above;
  • a halogen group is fluorine, chlorine, bromine, or iodine;
  • an aryl group denotes an aromatic group having five to fifteen carbon atoms, which can be substituted by one or more substituents R ⁇ where R ⁇ is as defined above; the aryl group is preferably a benzyl group
  • This heterocyclic group can be fused to another aromatic ring.
  • this group can be selected from a thiadiazole, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl. isooxazol-5-yl.
  • R 1 independently represents hydrogen, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl;
  • R 2 independently represents -NR 3 R 4 ,
  • R j independently represents ahcyl, cycloalkyl, alkoxy, alkylamine, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
  • R 4 independently represents alkyl, cycloalkyl, alkoxy, alkylamine, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
  • R 5 independently represents H, COR 6 , CO 2 R 6 , SOR 6 , SO 2 R 6 , SO 3 R 6 , alkyl, cycloalkyl, alkoxy, -NH 2 , alkylamine, -NR 7 COR 6 , halogen, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
  • R 6 independently represents H, alkyl, cycloalkyl, -NH 2 , alkylamine, aryl or heteroaryl
  • R 7 independently represents H, alkyl, cycloalkyl, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, aryl, or heteroaryl;
  • P is O, or 1; q is 0, or 1 ; x is CO or SO 2 .
  • X is preferably S or O, more preferably S.
  • R ,3 j a a is preferably H.
  • Z is CR and R and R together with the C-atom to which they are attached form a 6 membered saturated ring
  • Z is N and R 1 and R 2 together with the N-atom to which they are attached form a 6 membered saturated ring.
  • R 9 is preferably heteroaryl, aryl or benzyl, more preferably heteroaryl.
  • R 9 is even more preferably thienopyrimidine, quinazoline, purine, pyrazolopyrimidine or triazolpyrimidine. Even more preferably, R 9 is thienopyrimidine.
  • t is preferably 0.
  • r is preferably 1.
  • R 2a is preferably OH, alkyl, aryl or heteroaryl, more preferably alkyl, especially methyl.
  • the present invention relates also to compounds of the general formula (II) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs, or a stereoisomer thereof,
  • R 1 is -C(O)R 7 , -C(O)CHR 7 R 8 , -C(O)NR 7 R 8 , -C(O)OR 7 , -R 7 C(O)R 8 , or -C(S)R 7 ;
  • R 2 is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, alkylamino, hydroxyalkylamino, or heteroaryl; or R 1 and R 2 together with the N-atom or the C-atom to which they are attached form a 3 to 8 membered saturated or at least partially unsaturated monocyclic or polycyclic ring system, wherein at least one or more of the carbon atoms in the ring is a heteroatom selected from O, N, and S, and the ring can be substituted by one or more R 9 ;
  • R 3 is H, -C(O)NR a R b , halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR 4 OR 5' ,
  • R a is H, halogen, alkyl, -C(NR 7 )NR 7 R 8 , -(CH 2 ) p aryl, -(CH 2 ) P NR 7 R 8 , -C(O)NR 7 R 8 ,
  • -N CR 7 R 8 , -NR 7 C(O)R 8 , cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl;
  • R 6 is halogen, -C(O)R 7 , -C(O)CHR 7 R 8 , -C(O)NR 7 R 8 , -C(O)OR 7 , -R 7 C(O)R 8 , -C(S)R 7 ,
  • NR 7 C(O)R 7 alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl; 0 R 7 , R 7 , R 8 independently are H, halogen, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, -NHaryl, heteroaryl, or aryl; A is CO or SO 2; X is NR 2' , O, or S;
  • Y is N, CR 2' or if Y is O then R 6 is absent; 5 Z is N or CR 2' ; if Z is CH then X is O or NR 2'
  • R 2' is H, alkyl, -C(O)NR 2 , -C(0)R b , cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl; n is O to 2; p is 1 to 6; O q is 1 to 6;
  • R 9 independently represents H, -CN, -OH, -SH, -CO 2 R 4' , -C(0)R 4a , -C(O)NR 7 R 8 , -
  • NR 4' -CO-haloalkyl -NO 2 , -NR 4' -SO 2 -haloalkyl, -NR 4' -SO 2 -alkyl, -NR 4' -CO-alkyl, -NR 4 (CH 2 ) p heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, alkylamino, alkoxy, alkylthio, halogen, haloalkyl, haloalkyloxy, hydroxyalkylamino.
  • R 4a is H, Ci-C ⁇ -alkyl, Cr-C 6 -alkenyl, cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, -C(NR 7 )NR 7> R 8 , -(CH 2 ) p aryl, -(CH 2 ) P NR 7 R
  • a C]-C 6 -alkyl group if not stated otherwise, denotes a linear or branched Q-Q-alkyl, preferably a linear or branched chain of one to five carbon atoms, which can optionally be substituted by one or more substituents R";
  • a C 2 -C 6 -alkenyl group if not stated otherwise, denotes a linear or branched C 2 - C 6 -alkenyl, preferably a linear or branched chain of two to six carbon atoms, which can optionally be substituted by one or more substituents R' ;
  • an alkyl group if not stated otherwise, denotes a linear or branched CrQ-alkyl, preferably a linear or branched chain of one to six carbon atoms, a linear or branched C 2 -C 6 -alkenyl or a linear or branched C 2 -C 6 -alkynyl group, which can be substituted by one
  • This heterocyclic group can be fused to another aromatic ring.
  • this group can be selected from a thiadiazole, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, benzooxazol-2-yl.
  • This heterocyclic group can be substituted by one or more substituents R ⁇ wherein R ⁇ is as defined above.
  • R ⁇ is as defined above.
  • Z is S
  • Y is CO
  • X is CO
  • R is H
  • R c is H
  • R 1 is aryl, benzyl, or heteroaryL
  • R 2 is
  • R 5 is optionally substituted aryl, benzyl or heteroaryL
  • Z is O
  • Y is CO
  • X is CO
  • R is H
  • R c is H
  • R 1 is aryl, benzyl, or heteroaryl
  • R 2 is
  • R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • Z is S
  • Y is CO
  • X forms a piperidine ring together with R and R 4 , r R,a and R" is H
  • R c is H or methyl
  • R 2 is and R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • Z is O
  • Y is CO
  • X forms a piperidine ring together with R 1 and R 4
  • R a and R b is H
  • R c is H or methyl
  • R 2 is and R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • r is 1,Y is CO, Z is O, t is 0, s is 1, X is CO, R c is H, methyl, ethyl, methoxy, alkylamino, morpholino, N-
  • R 2 is and R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • r is 1,Y is CO, Z is S, t is 0, s is 0, R c is H, methyl, ethyl, methoxy, alkylamino, morpholino, N-methylpiperazine,
  • R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • r is 1,Y is CO, Z is S, t is 0, s is 1, X is CO, R c is H, methyl, ethyl, methoxy, alkylamino, morpholino, N-
  • R 2 is and R is optionally substituted aryl, benzyl or heteroaryl.
  • r is 1 ,Y is CO, Z is O, t is 0, s is 0, R c is H, methyl, ethyl, methoxy, alkylamino, morpholino, N-methylpiperazine,
  • R 5 is optionally substituted aryl, benzyl or heteroaryl.
  • a preferred embodiment of the invention, in the compounds of formula (III), are compounds of the formula (Ilia),
  • R 3 , R 4 , R 5 , R 7a and Z are defined as above.
  • R 3 is H, Me, OMe, CF 3 , OCF 3 , Cl, OH or SH, more preferably H, Me, OMe, CF 3 , OCF 3 , even more preferably H.
  • Z is N.
  • R 4 is H.
  • R 7a is aryl or heteroaryl, more preferably aryl, even more preferably phenyl. Further preferably, R 7a is substituted by one or two substituents R', more preferably by one substituent R'. In a particularly preferred embodiment, R 7a is 2-trifluormethoxyphenyl. In another particularly preferred embodiment, R 7a is 2-methoxyphenyl. In another particularly preferred embodiment, R 7a is 2-chlorophenyl. And in yet another particularly preferred embodiment, R 7a is 2-methylphenyl.
  • R 5 is aryl or heteroaryl, more preferably heteroaryl.
  • the heteroaryl contains preferably 2 nitrogen atoms and is particularly preferably 2-imidazolyl or 2- benzoimidazolyl, even more preferably 2-benzoimidazolyl.
  • the heteroaryl contains 1 nitrogen atom and 1 sulfur atom and is particularly preferably 2-thiazolyl or 2-benzothiazolyl, even more preferably 2-benzothiazolyl.
  • the heteroaryl further preferably is substituted by one to four substituents R', more preferably by one or two substituents R'.
  • R 5 is 5,6-dimethyl- lH-benzoimidazol-2-yl.
  • R 5 is 5,6-dimethyl- 1 H-benzothiazol-2-yl.
  • R is -SO 2 -alkyl, -NO 2 , halogen, -CO 2 H, -OH, haloalkyloxy, alkoxy or alkyl.
  • R' are the following: methanesulfonyl, nitro, fluorine, chlorine, bromine, carboxyl group, hydroxyl, trifluormethoxy, methoxy, ethoxy, methyl, ethyl or trifluoroethyl.
  • X is O. In another preferred embodiment X is S. In yet another preferred embodiment X is NR 2 .
  • R .3 i • s H, methyl, methoxy, CF 3 , or OCF 3 ; R 4 , R 5 , R 7a are defined as above; X is NR 2' , O or S; and Z is as defined as above.
  • R 3 is H, methyl, methoxy, CF 3 , or OCF 3 ;
  • R 5 is defined as above;
  • X is NR 2' , O or S; if Z is N then X is NR 2' , O or S; if Z is CR 2' then X is O; Y' is O or NR 2' , R 2' is as defined above.
  • R 11 , R 12 independently represent H, -CN, -OH, -SH, -CO 2 R 4' , -C(O)R 4' , -SO 2 NR 4' ,
  • R 7 and R 7' are defined as above;
  • NR 4 C(O)R 4" -NR , 4 *' -CO-haloalkyl, -NO 2 , -NR > 4*' -SO 2 -haloalkyl, -NR »4 * ' -SO 2 -alkyl, -NR 4 * ' - CO-alkyl, -NR 4 (CH 2 ) p heteroaryl, alkyl, cycloalkyl, alkylamino, alkoxy, alkylthio, - O(CH 2 ) p [O(CH 2 ) p ] q OCH 3 , -C(NR 4" )NR 4' benzimidazolyl, -C(NR 4" )NR 4' benzthiazolyl, - C(NR 4 )NR 4 benzoxazolyl hydroxyalkyl, hydroxycycloalkyl, hydroxyalkyl-amino, halogen, haloalkyl, haloalkyloxy
  • a more preferred embodiment of the invention in the compounds of formula (III), are compounds of the formula (HId),
  • R 3 is H, methyl, methoxy, CF 3 , or OCF 3 ;
  • X is NR 2' , O or S;
  • R 4 is defined as above;
  • R 7 and R 7 are defined as above;
  • Y" and R 11 , R 12 are defined as above under formula (IHc);
  • Y' is O or NR 2 and R 2 is as defined above.
  • Another more preferred embodiment of the invention, in the compounds of formula (III), are compounds of the formula (HIe),
  • R 3 , R 4 and R 5 are defined as above; X is O or S; R 11 and R 12 are defined as above under formula (IIIc); and if Z is N, X is NR 2' , O or S; if Z is CH, X is O.
  • Z is N or CH; R 3 is H, methyl, methoxy, CF 3 , or OCF 3 ; X is NR 2' , O or S; R 4 is defined as above; R 7 and R 7' are defined as above; R 2' is as defined above; Y" and R 11 , R 11 ' , R 12 , R 12' are defined as above under formula (IIIc).
  • a preferred embodiment of the invention are compounds of the formula (Iha),
  • R 1 is COR Va .
  • R 2 and R 3a are H; A is NH;
  • R 7 is as defined above;
  • X is NR 2' , O or S
  • R 3 is H, methyl, ethyl, methoxy, amine, alkylamine, morpholino, N-methylpiperazine, CF 3 , Or OCF 3 ; t is O; r is 1 ; and R 2a is optionally substituted aryl, benzyl or heteroaryl.
  • Another preferred embodiment of the invention in the compounds of formula (Ih), are compounds of the formula (Hia), wherein R 7a is optionally substituted aryl, benzyl or heteroaryl.
  • Y' is O or NR 2 Z '. ;
  • R 2 is as defined above;
  • R 3 is H, methyl, ethyl, methoxy, amine, alkylamine, morpholino, N-methylpiperazine, CF 3 , or OCF 3 ; t is O; r is 1 ; and
  • R 2a is optionally substituted aryl, benzyl or heteroaryl.
  • Z is preferably CR 2' .
  • Y' is preferably NR 2 '.
  • the R 2 in the NR 2 of Y is preferably substituted or unsubstituted heteroaryl.
  • the R in the NR 2 of Y is aryl.
  • the R 2 in the NR 2 of Y is benzyl, hi a more prefered embodiment, the R 2 in the NR 2 of Y is pyrimidine or triazine.
  • the R 2 in the NR 2 of Y is a substituted or unsubstituted bicyclic heteroaryl. More preferably thienopyrimidine, quinazoline, purine, pyrazolopyrimidine or triazolpyrimidine, even more preferably thienopyrimidine.
  • X is S. In another preferred embodiment, X is O. In yet another preferred embodiment, X is NR 2 . R 3 is preferably H.
  • R is preferably aryl or heteroaryl, more preferably phenyl.
  • R 3a is H; A is NH ; X is NR 2' , O or S;
  • R 11 and R 12 independently represent H, -CN, -OH, -SH, -CO 2 R 4' , -C(O)R 4' , -SO 2 NR 4' ,
  • R 4 , R 4 , R 5 are defined as above;
  • R 2 is as defined above;
  • R 3 is H, methyl, ethyl, methoxy, amine, alkylamine, morpholino, N-methylpiperazine, CF 3 , or OCF 3 ; t is O; r is 1 ; and R 2a is optionally substituted aryl, benzyl or heteroaryl.
  • X is S. In another preferred embodiment, X is O. In yet another preferred embodiment, X is NR v .
  • R is preferably -H, -CN, -OH, halogen, haloalkyl, haloalkyloxy, more preferably -CN.
  • R 12 is preferably H.
  • R 2a is preferably aryl or heteroaryl, more preferably phenyl.
  • a preferred embodiment of the invention, in the compounds of formula (II), are compounds of the formula (Ha),
  • R 1 and R 2 are defined as above; Z is defined as above; X is O or S; R 3 is H, methyl, methoxy, CF 3 , or OCF 3 ; R > ⁇ and R , 12 are defined as above under formula (HIc).
  • R 1 and R 2 are defined as above; Z is defined as above; X is O or S; R 3 is H, methyl, methoxy, CF 3 , or OCF 3 .
  • X is O or S
  • R J is H, methyl, methoxy, CF 3 , or OCF 3
  • Y' is NR Z
  • R 3 is H, methyl, methoxy, CF 3 , or OCF 3; R 11 , R n > and R 12 , R 12' are defined as above.
  • the present invention provides methods for preparing the compounds of the invention such as compounds of formula (Ia), (Ib), (Ic), (Ih), (II), or (III).
  • the compounds of formula (Ia), (Ib), (Ic), (Di), (II), or (III) may be obtained via various methods.
  • Piperidin-4yl-thiazole-4-carboxamide can be prepared by various methodes described in the literature.
  • One such example is the oxidation of the appropriate 2,5-dihydrothiazoles as described in Houben-Weyl, 2002, 730.
  • the dihydrothiazoles can also be synthesised by methodes described in the same reference or described in You, S., Razavi, H., Kelly, J. W. Angew. Chem. 2003, 115, 87 or Katritzky, AR., Cai, C, Suzuki, K., Singh, SK. J. Org. Chem. 2004, 69, 811-814 and references in both papers.
  • Alternative methods were described by Yasuchika, S. et. al. Heterocycles, Vol.
  • One possibility for the synthesis of compounds of formula (Ilia, c and Ha, b) comprises a step of reacting a compound of formula (V) with a compound of formula
  • 2-(l-(tert-butoxycarbonyl)piperidin-4-yl)thiazole-4-carboxylic acid can be converted to the appropriate R 1 amide by coupling with HBTU, DIPEA in DMF.
  • the different R 1 -amines are either commercially available or can be readily synthesized.
  • the Boc-protection group can be removed under standard conditions, such as treatment with TFA for 2 to 3 hours at 0° or with 4 N HCl in dioxane for 2 to 3 hours.
  • the deprotected piperidinoderivative HCl salt can then be converted to the corresponding amides, ureas and N-heterocyclic analogs as follows.
  • Urea substituted piperidino compounds can be synthesized by coupling with commercially available isocyanates in the presence of DIPEA.
  • Piperidino compounds substituted with heterocycles can be synthesized by standard procedures, such as coupling with the corresponding chloroheterocycle in the presence of a base.
  • piperidino compounds substituted with heterocycles can be obtained by palladium-mediated cross coupling.
  • hydroxypyridine derivatives can be coupled to the piperidino compound by the HBTU coupling method.
  • the Boc-protection group can be removed under standard conditions, such as treatment with TFA for 2 to 3 hours at 0° or with 4 N HCl in dioxane for 2 to 3 hours.
  • the deprotected piperidinoderivative HCl salt can then be converted to the corresponding N- heterocyclic analog by various methods as described as described above.
  • stereoisomer means cis/trans or E/Z isomerism. More particularly, the possible double bond(s) present in the various substituent of the compounds of the present invention can be E or Z configuration.
  • stereoisomer includes also all the isomeric forms, alone or as mixture, resulting from the presence of one or more axes and/or centres of symmetry in the molecules, and resulting in the rotation of a beam of polarized light. More particularly, it includes enatiomers and diastereomers, in pure form or as a mixture.
  • the compounds of the formula (Ia), (Ib), (Ic), (Di), (II), or (III) to be used according to the invention can form salts with inorganic or organic acids or bases.
  • pharmaceutically acceptable salts comprise without limitation non-toxic inorganic or organic salts such as acetate derived from acetic acid, aconitate derived from aconitic acid, ascorbate derived from ascorbic acid, benzoate derived from benzoic acid, cinnamate derived from cinnamic acid, citrate derived from citric acid, embonate derived from embonic acid, enantate derived from heptanoic acid, formiate derived from formic acid, fumarate derived from fumaric acid, glutamate derived from glutamic acid, glycolate derived from glycolic acid, chloride derived from hydrochloric acid, bromide derived from hydrobromic acid, lactate derived from lactic acid, maleate derived from maleic acid, malonate
  • salts like oxalate derived from oxalic acid which is not considered as pharmaceutically acceptable can be appropriate as intermediates for the production of compounds of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III) or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable prodrugs, or a stereoisomer thereof.
  • the invention covers the pharmaceutically acceptable salts, as indicated above, but also salts allowing a suitable seperation or crystallization of the compounds of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III), such as the salts obtained with chiral amines.
  • the compounds of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III) above also comprise the prodrugs of these compounds.
  • prodrug refers to compounds which once administered to the patient are not pharmaceutically active themselves ('prodrugs') but which are chemically and/or biologically transformed into their pharmaceutical active form (compounds of formula (Ia), (Ib), (Ic), (Ih), (II), or (III)) in vivo, i.e. in the subject to which the compound is administered.
  • Prodrugs include, for example, compounds of the invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups.
  • representative examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol, sulfhydryl and amine functional groups of the compounds of the present invention.
  • esters may be employed, such as methyl esters, ethyl esters, double esters and the like. Esters may be active in their own right and/or be hydrolysable under in vivo conditions in the human body.
  • the compounds according to the invention and medicaments prepared therewith are generally useful for the treatment of cell proliferation disorders, for the treatment or prophylaxis of immunological diseases and conditions (as for instance inflammatory diseases, neuroimmunological diseases, autoimmune diseases or other).
  • immunological diseases and conditions as for instance inflammatory diseases, neuroimmunological diseases, autoimmune diseases or other.
  • the compounds of the present invention are useful for the treatment of diseases which are caused by malignant cell proliferation, such as all forms of solid tumors, leukemias and lymphomas. Therefore the compounds according to the invention and medicaments prepared therewith are generally useful for regulating cell activation, cell proliferation, cell survival, cell differentiation, cell cycle, cell maturation and cell death or to induce systemic changes in metabolism such as changes in sugar, lipid or protein metabolism.
  • cell generation poiesis including blood cell growth and generation (prohematopoietic effect) after depletion or destruction of cells, as caused by, for example, toxic agents, radiation, immunotherapy, growth defects, malnutrition, malabsorption, immune dysregulation, anemia and the like or to provide a therapeutic control of tissue generation and degradation, and therapeutic modification of cell and tissue maintenance and blood cell homeostasis.
  • diseases and conditions include but are not limited to cancer as hematological (e.g. leukemia, lymphoma, myeloma) or solid tumors (for example breast, prostate, liver, bladder, lung, esophageal, stomach, colorectal, genitourinary, gastrointestinal, skin, pancreatic, brain, uterine, colon, head and neck, cervical, and ovarian, melanoma, astrocytoma, small cell lung cancer, glioma, basal and squameous cell carcinoma, sarcomas as Kaposi's sarcoma and osteosarcoma) or for the treatment of diseases which are cured or relieved by the inhibition of one or several kinases and/or phosphatases.
  • the compounds according to the invention and medicaments prepared therewith are particularly useful for the treatment of prostate cancer, melanoma, ovarial cancer and multiple myeloma.
  • Treatment is intended to mean complete or partial healing of a disease, or alleviation of a disease or stop of progression of a given disease.
  • the invention relates to the use of the compounds of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III) or a pharmaceutically acceptable salt or pharmaceutically acceptable prodrugs, or a stereoisomer thereof if desired with appropriate adjuvants and additives for the production of a medicament for the treatment or prevention of a disease characterized by hyperproliferation of keratinocytes and/or T cells, especially inflammatory disorders and immune disorders, preferably selected from the group consisting of Addison's disease, alopecia areata, Ankylosing spondylitis, haemolytic anemia (anemia haemolytica), pernicious anemia (anemia perniciosa), aphthae, aphthous stomatitis, arthritis, arteriosclerotic disorders, osteoarthritis, rheumatoid arthritis, aspermiogenese, asthma bronchiale, auto-immune asthma
  • the compounds according to the invention and medicaments prepared therewith are particularly useful for the treatment of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (in particular colitis and morbus crohn), inflammatory skin diseases (in particular neurodermitis and psoriasis) and lupus erythematosus.
  • autoimmune diseases and inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (in particular colitis and morbus crohn), inflammatory skin diseases (in particular neurodermitis and psoriasis) and lupus erythematosus.
  • the invention relates to a method of treatment or prevention of diseases which comprises the administration of an effective amount of compounds of the (Ia), (Ib), (Ic), (Ih), (II), or (III) or a pharmaceutically acceptable salt or pharmaceutically acceptable prodrugs, or a stereoisomer thereof.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (Ia), (Ib), (Ic), (Ih), (II), or (III), in free form or in the form of pharmaceutically acceptable salts and pharmaceutically acceptable prodrugs, together with a pharmaceutically acceptable diluent or carrier therefore.
  • the invention relates to the use of compounds of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III), or a pharmaceutically acceptable salt or pharmaceutically acceptable prodrugs or a stereoisomer thereof if desired with appropriate adjuvants and additives for the production of a medicament for the treatment or prevention of skin diseases in which T cells play a role; especially preferably the skin diseases are selected from the group consisting of psoriasis, atopic dermatitis, alopecia areata, alopecia totalis, alopecia subtotalis, alopecia universalis, alopecia diffusa, lupus erythematodes of the skin, lichen planus, dermatomyostis of the skin, atopic eczema, morphea, sklerodermia, psoriasis vulgaris, psoriasis capitis, psoriasis guttata, p
  • the compounds of the present invention can be used for the treatment of diseases resulting from ischemia and/or reperfusion injury of organs and/or of parts of the body selected from the group comprising heart, brain, peripheral limb, kidney, liver, spleen and lung, and/or wherein the endothelial dysfunction is associated with diseases selected from a group comprising infarctions such as myocardial infarction and critical limb ischemia,and/or wherein the endothelial dysfunction is associated with diseases selected from the group comprising ischemic diseases such as peripheral arterial occlusive disease, e. g. critical leg ischemia, myocardial infarction and ischemic diseases of organs, e. g. of the kidney, spleen, brain and lung.
  • diseases resulting from ischemia and/or reperfusion injury of organs and/or of parts of the body selected from the group comprising heart, brain, peripheral limb, kidney, liver, spleen and lung
  • the endothelial dysfunction is associated with diseases
  • the compounds of this invention also can be applied for the prevention and the treatment of neurological diseases or disorders (diseases or disorders associated with the brain and nervous system), including but not limited to, Alzheimer's disease, Parkinson's disease, Creutzfeld-Jacob Disease, Lewy Body Dementia, amyotrophic lateral sclerosis, stroke, epilepsy, multiple sclerosis, myasthenia gravis, Huntington's Disease, Down's Syndrome, nerve deafness, and Meniere's disease.).
  • neurological diseases or disorders dementias or disorders associated with the brain and nervous system
  • Other neurological diseases and disorders will be apparent to those of skill in the art and are encompassed by the definition as used in this invention.
  • the compounds according to the invention and medicaments prepared therewith are particularly useful for the treatment of stroke, reperfusion injury and Alzheimer's disease.
  • the compounds of the present invention can further be used for diseases that are caused by protozoal infestations in humans and animals.
  • Such veterinary and human pathogenic protozoas are preferably intracellular active parasites of the phylum Apicomplexa or Sarcomastigophora, especially Trypanosoma, Plasmodia, Leishmania, Babesia and Theileria, Cryptosporidia, Sacrocystida, Amoebia, Coccidia and Trichomonadia.
  • These active substances or corresponding drugs are especially suitable for the treatment of Malaria tropica, caused by Plasmodium falciparum, Malaria tertiana, caused by Plasmodium vivax or Plasmodium ovale and for the treatment of Malaria quartana, caused by Plasmodium malariae.
  • Toxoplasmosis caused by Toxoplasma gondii
  • Coccidiosis caused for instance by Isospora belli
  • intestinal Sarcosporidiosis caused by Sarcocystis suihominis
  • dysentery caused by Entamoeba histolytica
  • Cryptosporidiosis caused by Cryptosporidium parvum
  • Chargas disease, caused by Trypanosoma cruzi, sleeping sickness, caused by Trypanosoma brucei rhodesiense or gambiense, the cutaneous and visceral as well as other forms of Leishmaniosis.
  • veterinary pathogenic protozoa like Theileria parva, the pathogen causing bovine East coast fever, Trypanosoma congolense congolense or Trypanosoma vivax vivax, Trypanosoma brucei brucei, pathogens causing Nagana cattle disease in Africa, Trypanosoma brucei evansi causing Surra , Babesia bigemina, the pathogen causing Texas fever in cattle and buffalos, Babesia bovis, the pathogen causing European bovine Babesiosis as well as Babesiosis in dogs, cats and sheep, Sarcocystis ovicanis and ovifelis pathogens causing Sarcocystiosis in sheep, cattle and pigs, Cryptosporidia, pathogens causing Cryptosporidioses in cattle and birds, Eimeria and Isospora species, pathogens causing Coccidiosis in rabbit
  • the use of the compounds of the present invention is preferred in particular for the treatment of Coccidiosis or Malaria infections, or for the preparation of a drug or feed stuff for the treatment of these diseases.
  • This treatment can be prophylactic or curative, hi the treatment of malaria, the compounds of the present invention may be combined with other anti-malaria agents.
  • the compounds of the present invention can further be used for the prophylaxis and/or treatment of infectious diseases caused among others by bacteria and viruses, including opportunistic infections in a mammal, including a human.
  • Said method comprises administering to the mammal an amount of at least one compound of the general formula (Ia), (Ib), (Ic), (Ih), (II), or (III) and/or pharmaceutically acceptable salts thereof, effective to prevent and/or treat said infectious disease and/or opportunistic infection.
  • the infectious disease can be selected from the group comprising AIDS, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (Entamoeba histolytica Infection), Angiostrongylus Infection, Anisakiasis, Anthrax, Babesiosis (Babesia Infection), Balantidium Infection (Balantidiasis), Baylisascaris Infection (Raccoon Roundworm), Bilharzia (Schistosomiasis), Blastocystis hominis Infection (Blastomycosis), Boreliosis, Botulism, Brainerd Diarrhea, Brucellosis, BSE (Bovine Spongiform Encephalopathy), Candidiasis, Capillariasis (Capillaria Infection), CFS (Chronic Fatigue Syndrome), Chagas Disease (American Trypanosomiasis), Chickenpox (Varicella-Zoster virus), Chlamydia pneumonia
  • the compounds according to the invention and medicaments prepared therewith are particularly useful for the treatment of viral diseases, such as hepatits B, hepatitis C, influenza virus infections (in particular influenza A virus infections), AIDS (HIV infections) and human papilloma virus infections.
  • viral diseases such as hepatits B, hepatitis C, influenza virus infections (in particular influenza A virus infections), AIDS (HIV infections) and human papilloma virus infections.
  • the compounds according to the invention and medicaments prepared therewith are also particularly useful for the treatment of artheriosclerosis.
  • the compounds according to the invention and medicaments prepared therewith are further particularly useful for the treatment of osteoporosis.
  • the present invention relates to the use of a compound or a composition of the present invention for the preparation of a medicament for the treatment or prevention of a disease characterized by hyperproliferation of cells.
  • the present invention relates to the use of a compound or a composition of the present invention for the preparation of a medicament for the treatment or prevention of a disease resulting from ischemia and/or reperfusion injury of organs and/or of parts of the body selected from the group comprising heart, brain, peripheral limb, kidney, liver, spleen and lung, and/or wherein the endothelial dysfunction is associated with diseases selected from a group comprising infarctions such as myocardial infarction and critical limb ischemia, and/or wherein the endothelial dysfunction is associated with diseases selected from the group comprising ischemic diseases, myocardial infarction and ischemic diseases of organs.
  • the present invention relates to the use of a compound or a composition of the present invention for the preparation of a medicament for the treatment or prevention of a neurological diseases or disorders selected from the group comprising Alzheimer's disease, Parkinson's disease, Creutzfeld- Jacob Disease, Lewy Body Dementia, amyotrophic lateral sclerosis, stroke, epilepsy, multiple sclerosis, myasthenia gravis, Huntington's Disease, Down's Syndrome, nerve deafness, and Meniere's disease.
  • a neurological diseases or disorders selected from the group comprising Alzheimer's disease, Parkinson's disease, Creutzfeld- Jacob Disease, Lewy Body Dementia, amyotrophic lateral sclerosis, stroke, epilepsy, multiple sclerosis, myasthenia gravis, Huntington's Disease, Down's Syndrome, nerve deafness, and Meniere's disease.
  • the compounds of formula (Ia), (Ib), (Ic), (Di), (II), or (III) and their pharmacologically acceptable salts can be administered to animals, preferably to mammals, and in particular to humans, dogs and chickens as therapeutics per se, as mixtures with one another or in the form of pharmaceutical preparations which allow enteral or parenteral use and which as active constituent contain an effective dose of at least one compound of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III) or a salt thereof, in addition to customary pharmaceutically innocuous excipients and additives.
  • the compounds of formula (Ia), (Ib), (Ic), (Di), (II), or (III) can also be administered in form of their salts, which are obtainable by reacting the respective compounds with physiologically acceptable acids and bases.
  • the compounds of formula (Ia), (Ib), (Ic), (Di), (II), or (III) according to the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • Such salts of the compounds may be anhydrous or solvated.
  • the invention provides medicaments comprising compounds of formula (Ia), (Ib), (Ic), (Ih), (II), or (III) according to the invention, or a pharmaceutically acceptable salt or pharmaceutically acceptable prodrugs or a stereoisomer thereof, together with one or more pharmaceutically acceptable carriers thereof, and. optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • a medicament of the invention may be those suitable for oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • the compounds according to the invention may thus be placed into the form of medicament and unit dosages thereof.
  • forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such Medicament and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the compound useable according to the invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of formula (Ia), (Ib), (Ic), (Ih), (II), or (III) according to the invention or a pharmaceutically acceptable salt or stereosomer thereof.
  • pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation” is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the compounds of formula (Ia), (Ib), (Ic), (Di), (II), or (III) according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the medicament is applied topically or systemically or via a combination of the two routes.
  • the medicament is applied topically. This reduces possible side effects and limits the necessary treatment to those areas affected.
  • the medicament is prepared in form of an ointment, a gel, a plaster, an emulsion, a lotion, a foam, a cream of a mixed phase or amphiphilic emulsion system (oil/water-water/oil mixed phase), a liposome, a transfersome, a paste or a powder.
  • an ointment a gel, a plaster, an emulsion, a lotion, a foam, a cream of a mixed phase or amphiphilic emulsion system (oil/water-water/oil mixed phase), a liposome, a transfersome, a paste or a powder.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • the powder carrier will form a gel in the nasal cavity
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
  • compositions can also contain two or more compounds of the formula (Ia), (Ib), (Ic), (Ih), (II), or (III) or their pharmacologically acceptable salts and also other therapeutically active substances.
  • the compounds of the present invention can be used in the form of one compound alone or in combination with other active compounds - for example with medicaments already known for the treatment of the aforementioned diseases, whereby in the latter case a favorable additive, amplifying effect is noticed.
  • Suitable amounts to be administered to humans may range from 5 to 500 mg.
  • pharmaceutically inert inorganic or organic excipients can be used.
  • pills tablets, coated tablets and hard gelatin capsules, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts, etc.
  • Excipients for soft gelatin capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils etc.
  • Suitable excipients for the production of solutions and syrups are, for example, water, sucrose, invert sugar, glucose, polyols etc.
  • Suitable excipients for the production of injection solutions are, for example, water, alcohols, glycerol, polyols or vegetable oils.
  • the dose can vary within wide limits and is to be suited to the individual conditions in each individual case.
  • the appropriate dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, however, satisfactory results are achieved at dosage rates of about 1 to 100 mg/kg animal body weight preferably 1 to 50 mg/kg.
  • suitable dosage rates for larger mammals, for example humans may be of the order of from about 10 mg to 3 g/day, conveniently administered once, in divided doses 2 to 4 times a day, or in sustained release form.
  • a daily dose of approximately 10 mg to 5000 mg, preferably 50 to 500 mg, per human individual is appropriate in the case of the oral administration. In the case of other administration forms too, the daily dose is in similar ranges.
  • concentrations of active compounds within the medicament can be sufficient to elicit a therapeutic effect by topical application.
  • concentration of an active compound or a pharmaceutically acceptable salt thereof or a physiologically functional derivative or a stereoisomer thereof within a medicament according to the invention is in the range of between 1 ⁇ mol/1 and 100 mmol/1.
  • Preparative HPLC-MS Waters 600 Multisolvent Delivery System with peparative pump heads. 2000 ⁇ l or 5000 ⁇ l sample loop. Column, Waters X-Terra RPl 8, 7 ⁇ m, 19 x 150 mm with X-Terra RP 18 guard cartridge 7 ⁇ m, 19 x 10 mm; used at flow rate 20 ml/min or YMC ODS-A, 120 A, 40 x 150 mm with X-Terra RP 18 guard cartridge 7 ⁇ m, 19 x 10 mm; used at flow rate 50 ml/min.
  • Piperidine-l,4-dicarboxylic acid mono-tert-butyl ester (1.0 eq, 21.8 mmol) was dissolved under inert conditions in 35 ml dry N, N- dimethylformamide.
  • O,N-dimethyl- hydroxylamine hydrochloride (1.03 eq, 22.5 mmol)
  • benzotriazol-1-ol monohydrate (1.03 eq, 22.5 mmol
  • triethylamine 1.5 eq, 32.7 mmol
  • reaction mixture was cooled to 0°C, N-(3-Dimethylaminopropyl)-N-ethylcarbodiimid hydrochloride (1.0 eq, 21.8 mmol) was added over a period of 10 minutes and the mixture was stirred vigorously at 0 0 C for 1 h and at r.t. for 18 h.
  • the solvent was removed under vaccum and the residue was suspended in 400 ml ethylacetate.
  • the organic layer was extracted 3 times with 100 ml of 1 M citric acid, aqueous sodium carbonate and twice with 100 ml brine, dried over MgSO 4 and filtered.
  • the solvent was removed and the residue was purified by distillation resulting in a yield of 80%.
  • the mixture was cooled to -78 0 C and quenched carefully with 100 ml 1 M citric acid.
  • the mixture was warmed up to r.t. and diluted with 400 ml ethylacetate.
  • the phases were separated and the aqueous phase was extracted 3 times with 70 ml ethylacetate.
  • the combined organic layers were extracted 3 times with 100 ml 1 M citric acid, aqueous sodium carbonate and 2 times with 100 ml brine, dried over MgSO 4 and filtrated.
  • the solvent was removed and the residue was purified by distillation resulting in a yield of 85%
  • N-terminal functionalisation The N-protected substrate was treated under inert condition with 4 M HCl/dioxane (cone. 0,03 mmol substrate in 1 mL HCl/dioxane) and was stirred for 2 h at r.t. The solvent was removed in vacuo to yield the HCl salt of the free amine without further purification. The free amino compound (1 eq) was dissolved under inert conditions in dry dimethylacetamide (0,03 mmol/ml).
  • intermediate (VII) was dissolved in 3 ml DMF and 1 eq. of H ⁇ nig's base was added, stirring the reaction mixture for a few minutes, followed by the addition of 1 eq. of HBTU and further stirring at r.t. for 2 min. Afterwards 1 eq. the amino component was added, stirring the mixture overnight at the same temperature. Subsequently, the solvent was removed by filtration and the crude product redissolved in 10 ml ethyl acetate, washed twice with 10 ml citric acid (IM solution), 10 ml sat. NaHCO 3 solution and 10 ml water. The organic phase was then evaporated and the residue dried over MgSO 4 .
  • IM solution 10 ml citric acid
  • 10 ml sat. NaHCO 3 solution 10 ml water
  • Exemplary compounds of formula (Ia) of the present invention include, but are not limited to, the following:
  • the biological data refer to results obtained from the NF- ⁇ B inflammation assay.
  • Exemplary compounds of formula (Ib) of the present invention include, but are not limited to, the following:
  • the biological data refer to results obtained from the NF- ⁇ B inflammation assay.
  • Exemplary compounds of formula (Ic) of the present invention include, but are not limited to, the following:
  • the biological data refer to results obtained from the NF- ⁇ B inflammation assay.
  • Exemplary compounds of formula (II) of the present invention include, but are not limited to, the following:
  • the biological data refer to results obtained from the NF- ⁇ B inflammation assay.
  • Exemplary compounds of formula (III) of the present invention include, but are not limited to, the following:
  • the biological data refer to results obtained from the NF- ⁇ B inflammation assay.
  • Exemplary compounds of formula (Di) of the present invention include, but are not limited to, the following:
  • Exemplary compounds of formula (Ilia) of the present invention include, but are not limited to, the following:
  • the biological data refer to results obtained from the NF- ⁇ B inflammation assay.
  • the chymotryptic activity of the 2OS proteasome was determined using a Tecan Ultra plate reader and Suc-LL VT-AMC as substrate (Bachem).
  • 2 ⁇ l of the respective inhibitor dissolved in DMSO were mixed with 50 ⁇ l substrate solution (25 mM HEPES pH 7.5 at 2O 0 C, 0.5 mM EDTA and Suc-LL VT- AMC (in the appropriate concentration) and the reaction was initiated by adding 150 ⁇ l proteasome solution (1.3 ⁇ g/ml 2OS proteasome in 25 mM HEPES pH 7.5 at 20°C, 0.5 mM EDTA, 0.033% (w/v) SDS).
  • Substrate hydrolysis was followed by fluorescence spectroscopy (excitation wavelength: 360 nm; emission wavelength: 465 nm) for 20 min at 30 0 C and initial velocities were calculated and expressed as change in relative fluorescence units (RFU) per second.
  • fluorescence spectroscopy excitation wavelength: 360 nm; emission wavelength: 465 nm
  • initial velocities were calculated and expressed as change in relative fluorescence units (RFU) per second.
  • IC 50 values concentration of inhibitor required for 50% inhibition
  • PBMC peripheral blood monocytes
  • PBMCs peripheral blood mononuclear cells
  • PBMCs peripheral blood mononuclear cells
  • the cells were stimulated with 2 ⁇ g/ml phytohemoagglutinin in the presence of test compound or blank vehicle for 72 h. 4 h prior to the end of the incubation period, 5-bromo-2'- desoxyuridine (BrdU) was added to label the proliferating cells. After the incubation, the cells were separated by centrifugation and the culture supernatant removed.
  • PrdU 5-bromo-2'- desoxyuridine
  • Incorporated BrdU was quantified with the help of an enzyme-linked immunosorbent assay. For the determination of the IC 50 values (concentration of inhibitor required for 50% inhibition) at least four different inhibitor concentrations were applied. Each data point was recorded in triplicates. Curves were fitted with the a suitable program. Based on results obtained in the T-lymphocyte proliferation assay, the compounds of the present invention are suitable for treating inflammatory diseases or diseases associated with T-cells.
  • NF- ⁇ B-induced inflammation For the determination of anti-inflammatory activity of the compounds the PRINCESS® NINA Instant Assay from Cell Culture Service GmBH was used. This assay is based on recombinant A549-NF-KB-SEAP reporter cells preseeded in 96-well flat bottom plates. As the transfected reporter gene for SEAP (secreted embryonic alkaline phosphatase) is under transcriptional control of a NF- ⁇ B-responsive element, the expression of this reporter is activated upon stimulation with TNF- ⁇ . SEAP secretion into the culture supernatant can be detected by the chemiluminescent substrate CSPD®.
  • SEAP secretion into the culture supernatant can be detected by the chemiluminescent substrate CSPD®.
  • Test compounds that inhibit the NF- KB activation show reduced SEAP activity and reduced luminescent readout.
  • the cells were incubated with 0.01 up to 100 ⁇ M of test compound for 4.5 h before stimulation with 2ng/ml TNF- ⁇ .
  • endogenous phosphatases were inactivated and CSPD® substrate was supplied for 40 min.
  • SEAP activity then was quantified by measuring luminescence as relative light units (RLU) using a Tecan Ultra reader. Each data point was recorded in quadruplicates and EC50 values were calculated via fitting function and the Microsoft Excel Solver.

Abstract

L'invention concerne des composés de formule générale (Ih) ou des sels pharmaceutiquement acceptables de ceux-ci associés à un acide ou à une base, ou des promédicaments pharmaceutiquement acceptables de ceux-ci ou un stéréoisomère de ceux-ci. Dans la formule (Ih), A désigne NR2, S ou O; R3a désigne H, OH, SH, NH2, -C(NR7)NR7'R8, -(CH2)paryle, -(CH2)PNR7R8, -C(O)NR7R8, -N=CR7R8, -NR7C(O)R8, alkyle, cycloalkyle, hydroxyalkyle, haloalkyle, haloalkyloxy, alkoxy, alkylamine, hydroxyalkylamine, halogène, aryle, ou hétéroaryle; R3 désigne H, -C(0)NRaRb, halogène, alkyle, haloalkyle, aryle, hétéroaryle, OH, SH, NR4' OR5', NH2, hydroxyalkylamine, alkylamine, alkoxy, cycloalkyle, hétéro- cycloalkyle, hydroxyalkyle, ou haloalkyloxy; X désigne NR2', O, ou S; Z désigne N ou CR2'.
EP07711946A 2006-03-15 2007-03-14 Nouveaux inhibiteurs hétérocycliques de nf/kb Withdrawn EP1994017A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07711946A EP1994017A2 (fr) 2006-03-15 2007-03-14 Nouveaux inhibiteurs hétérocycliques de nf/kb

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/375,259 US7601745B2 (en) 2004-09-27 2006-03-15 Heterocyclic NF-kB inhibitors
PCT/EP2006/002396 WO2007016979A2 (fr) 2005-07-29 2006-03-15 Nouveaux inhibiteurs heterocycliques de nf-kb
PCT/EP2007/002265 WO2007104557A2 (fr) 2006-03-15 2007-03-14 Nouveaux inhibiteurs hétérocycliques de nf/kb
EP07711946A EP1994017A2 (fr) 2006-03-15 2007-03-14 Nouveaux inhibiteurs hétérocycliques de nf/kb

Publications (1)

Publication Number Publication Date
EP1994017A2 true EP1994017A2 (fr) 2008-11-26

Family

ID=38461965

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07711946A Withdrawn EP1994017A2 (fr) 2006-03-15 2007-03-14 Nouveaux inhibiteurs hétérocycliques de nf/kb

Country Status (3)

Country Link
EP (1) EP1994017A2 (fr)
CN (1) CN101405278A (fr)
WO (1) WO2007104557A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A2 (fr) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Inhibiteurs de la kinase aurora
CA2682050A1 (fr) * 2007-03-27 2008-10-02 4Sc Ag Composition pharmaceutique comprenant une cytokine
EP2190843A1 (fr) * 2007-09-19 2010-06-02 4Sc Ag Inhibiteurs de nf-kappab du type benzimidazole
DE102007047735A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
CA2703106C (fr) * 2007-10-24 2015-12-01 Astellas Pharma Inc. Derives d'azolecarboxamide comme inhibiteurs de trka
CA2707445A1 (fr) * 2007-11-30 2009-06-11 Biota Scientific Management Pty Ltd Inhibiteurs tetrahydro-isoquinolino de ppat utilises en tant qu'agents antibacteriens
EP2225250A2 (fr) 2007-11-30 2010-09-08 Biota Scientific Management Pty Ltd Inhibiteurs de ppat bicycliques utilisés en tant qu'agents antibactériens
WO2009080546A1 (fr) * 2007-12-21 2009-07-02 Basf Se Utilisation de composés 6-halogéno-[1,2,4]-triazolo-[1,5-a]-pyrimidine dans la lutte contre les nuisibles chez l'animal
EA201300759A1 (ru) * 2008-05-05 2013-11-29 Мерк Патент Гмбх Новые производные nip тиазола в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы-1
US8716312B2 (en) * 2008-11-19 2014-05-06 Merck Sharp & Dohme Corporation Inhibitors of diacylglycerol acyltransferase
KR101051077B1 (ko) * 2008-12-05 2011-07-21 한국화학연구원 2-피페라지노-4,5-이중치환-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제
EP2376491B1 (fr) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines en tant qu'inhibiteurs d'alk et de jak2
FR2969611B1 (fr) * 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
CN104356127B (zh) * 2014-11-13 2017-06-16 重庆理工大学 含n双杂环酰胺类化合物及其作为免疫抑制剂的应用
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
EP4251622A1 (fr) * 2020-11-25 2023-10-04 F. Hoffmann-La Roche AG Dérivés d'amides cycliques pontés aromatiques pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
CN114712503B (zh) * 2021-10-09 2023-05-26 浙江大学 c-Abl抑制剂在制备预防和/或治疗肌萎缩性侧索硬化症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
US20050209284A1 (en) * 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
JP2008513386A (ja) * 2004-09-20 2008-05-01 ４エスシー アーゲー 新規な複素環式ＮＦ−κＢ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007104557A2 *

Also Published As

Publication number Publication date
CN101405278A (zh) 2009-04-08
WO2007104557A3 (fr) 2008-05-22
WO2007104557A2 (fr) 2007-09-20

Similar Documents

Publication Publication Date Title
US7601745B2 (en) Heterocyclic NF-kB inhibitors
US7812041B2 (en) Heterocyclic NF-κB inhibitors
US8106048B2 (en) Heterocyclic NF-κB inhibitors
EP1994017A2 (fr) Nouveaux inhibiteurs hétérocycliques de nf/kb
WO2007104558A1 (fr) Thiazoles servant d'inhibiteurs de nf/kb (inhibiteurs du protéasome)
WO2007016979A2 (fr) Nouveaux inhibiteurs heterocycliques de nf-kb
US20120022068A1 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
AU2007224659A1 (en) Novel heterocyclic NF-KB inhibitors
EP1912982A2 (fr) Nouveaux inhibiteurs heterocycliques de nf-kb
MX2008001356A (en) NOVEL HETEROCYCLIC NF-κB INHIBITORS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081007

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRAUSS, ROLF

Inventor name: WUZIK, ANDREAS

Inventor name: PEGORARO, STEFANO

Inventor name: WOLF, KRISTINA

Inventor name: SCHMITT, HARALD

Inventor name: LEBAN, JOHANN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 4SC DISCOVERY GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121002